Since CREB1 mRNA expression predicts metastatic recurrence better than biochemical recurrence this suggests that the metastatic subgroup of PCa patients with high CREB expression have a greater risk of developing metastatic disease progression. The gene discussed is CREB1; the disease is posterior cortical atrophy.